非霍奇金淋巴瘤中的B细胞受体通路调节剂
B-cell receptor pathway modulators in NHL.
作者信息
Blum Kristie A
机构信息
Division of Hematology, The Ohio State University, Columbus, OH.
出版信息
Hematology Am Soc Hematol Educ Program. 2015;2015:82-91. doi: 10.1182/asheducation-2015.1.82.
Abstract
With the recent success of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, and the phosphoinositide-3-kinase (PI3K) inhibitor, idelalisib, in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), a number of new agents targeting the B-cell receptor (BCR) pathway are in clinical development. In addition, multiple trials combining these agents with conventional cytotoxic chemotherapy, immunomodulatory agents, monoclonal antibodies, or other kinase inhibitors are underway. This review will summarize the current data with the use of single agent and combination therapy with BCR inhibitors in NHL. In addition, commonly encountered as well as serious toxicities and hypothesized resistance mechanisms will be discussed. Lastly, this review will examine the future of these agents and opportunities to maneuver them into the front-line setting in selected NHL subtypes.
摘要
随着布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼以及磷酸肌醇-3-激酶（PI3K）抑制剂idelalisib在复发或难治性非霍奇金淋巴瘤（NHL）患者治疗中取得的近期成功，一些靶向B细胞受体（BCR）通路的新型药物正处于临床开发阶段。此外，多项将这些药物与传统细胞毒性化疗、免疫调节剂、单克隆抗体或其他激酶抑制剂联合使用的试验正在进行中。本综述将总结目前在NHL中使用BCR抑制剂进行单药治疗和联合治疗的数据。此外，还将讨论常见及严重毒性以及推测的耐药机制。最后，本综述将探讨这些药物的未来发展以及将它们应用于特定NHL亚型一线治疗的机会。
相似文献
1
B-cell receptor pathway modulators in NHL.非霍奇金淋巴瘤中的B细胞受体通路调节剂
Hematology Am Soc Hematol Educ Program. 2015;2015:82-91. doi: 10.1182/asheducation-2015.1.82.
2
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.靶向 B 细胞受体通路：非霍奇金淋巴瘤当前和未来治疗方法的综述。
Expert Opin Emerg Drugs. 2018 Jun;23(2):111-122. doi: 10.1080/14728214.2018.1479396. Epub 2018 Jun 6.
3
Targeting of B-cell receptor signalling in B-cell malignancies.靶向 B 细胞受体信号转导在 B 细胞恶性肿瘤中的作用。
J Intern Med. 2017 Nov;282(5):415-428. doi: 10.1111/joim.12600. Epub 2017 Mar 14.
4
Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110 as a Therapeutic Approach to Treat Non-Hodgkin's B Cell Malignancies.布鲁顿酪氨酸激酶和磷酸肌醇-3-激酶p110的双重抑制作为治疗非霍奇金B细胞恶性肿瘤的一种治疗方法。
J Pharmacol Exp Ther. 2017 May;361(2):312-321. doi: 10.1124/jpet.116.238022. Epub 2017 Mar 15.
5
Targeting the B cell receptor pathway in non-Hodgkin lymphoma.针对非霍奇金淋巴瘤的 B 细胞受体途径。
Expert Opin Investig Drugs. 2018 Jun;27(6):513-522. doi: 10.1080/13543784.2018.1482273. Epub 2018 Jun 7.
6
PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.PI3Kδ抑制剂idelalisib联合BTK抑制剂ONO/GS-4059用于对PI3Kδ和BTK抑制剂获得性耐药的弥漫性大B细胞淋巴瘤
PLoS One. 2017 Feb 8;12(2):e0171221. doi: 10.1371/journal.pone.0171221. eCollection 2017.
7
Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.协同靶向成熟 B 细胞恶性肿瘤中 PI3Kδ 的调节亚基和催化亚基。
Clin Cancer Res. 2018 Mar 1;24(5):1103-1113. doi: 10.1158/1078-0432.CCR-17-2218. Epub 2017 Dec 15.
8
Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.Myc增强癌前B细胞中的B细胞受体信号传导，并赋予对Btk抑制的抗性。
Oncogene. 2017 Aug 10;36(32):4653-4661. doi: 10.1038/onc.2017.95. Epub 2017 Apr 3.
9
BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.慢性淋巴细胞白血病中的 BCR 信号转导及目前处于临床研究阶段的相关抑制剂。
Int Rev Immunol. 2013 Aug;32(4):358-76. doi: 10.3109/08830185.2013.786711. Epub 2013 Apr 25.
10
B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.B细胞受体信号传导及其在正常细胞和恶性细胞中与其他信号通路的相互作用。
Eur J Haematol. 2015 Mar;94(3):193-205. doi: 10.1111/ejh.12427. Epub 2014 Sep 13.
引用本文的文献
1
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.靶向癌症治疗中的小分子：进展、挑战和未来展望。
Signal Transduct Target Ther. 2021 May 31;6(1):201. doi: 10.1038/s41392-021-00572-w.
2
Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2.抑制B细胞受体信号传导通过RAC2破坏套细胞淋巴瘤中的细胞黏附。
Blood Adv. 2021 Jan 12;5(1):185-197. doi: 10.1182/bloodadvances.2020001665.
3
BCALM (AC099524.1) Is a Human B Lymphocyte-Specific Long Noncoding RNA That Modulates B Cell Receptor-Mediated Calcium Signaling.BCALM（AC099524.1）是一种人类 B 淋巴细胞特异性长非编码 RNA，可调节 B 细胞受体介导的钙信号转导。
J Immunol. 2020 Aug 1;205(3):595-607. doi: 10.4049/jimmunol.2000088. Epub 2020 Jun 22.
4
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.新型 BCL-2 抑制剂 APG-2575 联合 BTK 或 MDM2-p53 抑制剂在弥漫大 B 细胞淋巴瘤中发挥合成致死作用。
Oncol Res. 2020 Sep 1;28(4):331-344. doi: 10.3727/096504020X15825405463920. Epub 2020 Feb 24.
5
Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?我们是否准备好根据主要基因亚型来治疗弥漫性大B细胞淋巴瘤和高级别淋巴瘤？
Hemasphere. 2019 Jul 31;3(5):e284. doi: 10.1097/HS9.0000000000000284. eCollection 2019 Oct.
6
A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib.利妥昔单抗联合伊布替尼治疗非生发中心B细胞型弥漫性大B细胞淋巴瘤达完全缓解1例报告
Case Rep Hematol. 2018 Mar 13;2018:5471368. doi: 10.1155/2018/5471368. eCollection 2018.
7
Gene mutations and actionable genetic lesions in mantle cell lymphoma.套细胞淋巴瘤中的基因突变及可靶向治疗的基因损伤
Oncotarget. 2016 Sep 6;7(36):58638-58648. doi: 10.18632/oncotarget.10716.
本文引用的文献
1
A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).一项评估福他替尼对复发或难治性弥漫性大B细胞淋巴瘤（DLBCL）患者疗效的II期试验。
Eur J Cancer. 2016 Feb;54:11-17. doi: 10.1016/j.ejca.2015.10.005. Epub 2015 Dec 18.
2
Ibrutinib in previously treated Waldenström's macroglobulinemia.伊布替尼治疗既往治疗的华氏巨球蛋白血症。
N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548.
3
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.布鲁顿酪氨酸激酶（BTK）和白细胞介素-2诱导激酶（ITK）的抑制剂依鲁替尼可增强检查点阻断的治疗性抗肿瘤免疫。
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E966-72. doi: 10.1073/pnas.1500712112. Epub 2015 Feb 17.
4
Management of adverse events associated with idelalisib treatment: expert panel opinion.idelalisib治疗相关不良事件的管理：专家小组意见
Leuk Lymphoma. 2015;56(10):2779-86. doi: 10.3109/10428194.2015.1022770. Epub 2015 May 19.
5
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.套细胞淋巴瘤患者伊布替尼治疗失败后，不太可能对挽救性化疗有反应，且预后不良。
Ann Oncol. 2015 Jun;26(6):1175-1179. doi: 10.1093/annonc/mdv111. Epub 2015 Feb 23.
6
Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.布鲁顿酪氨酸激酶抑制剂在 B 细胞非霍奇金淋巴瘤中的应用。
Clin Pharmacol Ther. 2015 May;97(5):469-77. doi: 10.1002/cpt.65. Epub 2015 Jan 20.
7
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.依鲁替尼增强了瘤内注射TLR9配体在小鼠淋巴瘤中诱导的抗肿瘤免疫反应。
Blood. 2015 Mar 26;125(13):2079-86. doi: 10.1182/blood-2014-08-593137. Epub 2015 Feb 6.
8
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.弥漫性大 B 细胞淋巴瘤：在临床和生物学异质性的背景下优化治疗结局。
Blood. 2015 Jan 1;125(1):22-32. doi: 10.1182/blood-2014-05-577189. Epub 2014 Dec 11.
9
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.一项利妥昔单抗、苯达莫司汀和伊布替尼治疗未经治疗和复发/难治性非霍奇金淋巴瘤患者的 1 期/1b 期研究。
Blood. 2015 Jan 8;125(2):242-8. doi: 10.1182/blood-2014-08-597914. Epub 2014 Oct 29.
10
Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.依鲁替尼与ABT-199联合使用：通过干扰BTK、AKT和BCL2信号通路对套细胞淋巴瘤细胞的增殖抑制和凋亡产生协同作用。
Br J Haematol. 2015 Mar;168(5):765-8. doi: 10.1111/bjh.13149. Epub 2014 Oct 4.
Zotero 插件